Asselah, J. and Sperlich, C. (2013) “Post-docetaxel options for further survival benefit in metastatic castration-resistant prostate cancer: Questions of choice”, Canadian Urological Association Journal, 7(1-2-S1), pp. S11-S17. doi: 10.5489/cuaj.274.